

STATE OF CONNECTICUT
DEPARTMENT OF CONSUMER PROTECTION
NOTICE OF INTENT TO AMEND REGULATIONS

In accordance with the authority granted in Sections 4-168 and 20-631 of the Connecticut General Statutes, it is the intention of the State of Connecticut, Department of Consumer Protection to amend the Regulations of Connecticut State Agencies by adding Sections 20-631-1 through to 20-631-3, concerning collaborative drug therapy management.

All interested persons who wish to express their views orally may do so at a public hearing to be held at the Department of Consumer Protection, Room 119, State Office Building, 165 Capitol Avenue, Hartford, Connecticut 06106 at 10:00 a.m. on June 4, 2012.

All interested parties who wish to submit data, views or arguments may do so in writing within thirty (30) days following the publication of this notice. Such written materials should be directed to William M. Rubenstein, Commissioner, Department of Consumer Protection, Room 103, State Office Building, 165 Capitol Avenue, Hartford, Connecticut, 06106.

A copy of the proposed regulation, the Fiscal Note, and the Small Business Impact Statement applicable to the proposed regulation (as required by Public Act 09-19) are available for inspection at the address cited above, by requesting a copy of the same by telephoning the Department at 860-713-6086, or by viewing the same by clicking on the "Laws and Regulations" link on the Internet homepage of the Department: www.CT.gov/DCP.

The proposed changes are summarized as follows:

These regulations establish requirements for collaborative drug therapy agreements between physicians and pharmacists. Section 91 of Public Act 10-117 requires the Commissioner of Consumer Protection to adopt these regulations.

These regulations establish: 1. the competency requirements for pharmacists to qualify for participation in a drug therapy management

agreement; 2. the minimum content of a collaborative drug therapy management agreement; and 3. the content of the written protocol for each patient. The Department of Public Health was consulted in drafting these regulations, pursuant to Section 20-631(b) of the General Statutes, as amended by Section 91 of Public Act 10-117.

These regulations establish requirements for collaborative drug therapy agreements between physicians and pharmacists. If a pharmacist enters into a collaborative drug therapy agreement but fails to comply with these regulations, he or she may face administrative action against the pharmacist's license. The administrative remedies include revocation or suspension of the license, probation, civil penalties or a letter of reprimand.